Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398

By: via Benzinga
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced Phase 1 results from a clinical pilot study demonstrating that ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.